CMP-5 |
| Katalog-Nr.GC39665 |
CMP-5 ist ein potenter, spezifischer und selektiver PRMT5-Inhibitor, wÄhrend es keine AktivitÄt gegen PRMT1-, PRMT4- und PRMT7-Enzyme zeigt. CMP-5 blockiert selektiv S2Me-H4R3, indem es die PRMT5-Methyltransferase-AktivitÄt auf HistonprÄparaten hemmt. CMP-5 verhindert die vom Epstein-Barr-Virus (EBV) getriebene B-Lymphozyten-Transformation, lÄsst aber normale B-Zellen unbeeinflusst.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 880813-42-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CMP-5 is a potent, specific, and selective PRMT5 inhibitor, while displays no activity against PRMT1, PRMT4, and PRMT7 enzymes. CMP-5 selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. CMP-5 prevents Epstein-Barr virus (EBV)-driven B-lymphocyte transformation but leaving normal B cells unaffected[1][2].
[1]. Alinari L, et al. Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.Blood. 2015 Apr 16;125(16):2530-43. [2]. Webb LM, et al. PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis. J Immunol. 2017 Feb 15;198(4):1439-1451.
Average Rating: 5 (Based on Reviews and 4 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *